Sonova (OTCMKTS:SONVY) Upgraded to Hold at Zacks Research

Sonova (OTCMKTS:SONVY) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other analysts also recently weighed in on SONVY. Royal Bank Of Canada upgraded Sonova to a “moderate buy” rating in a research note on Tuesday, November 18th. BNP Paribas Exane began coverage on Sonova in a research report on Monday, October 20th. They set an “underperform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Sonova has a consensus rating of “Hold”.

Sonova Trading Down 0.2%

OTCMKTS:SONVY opened at $53.40 on Monday. Sonova has a one year low of $47.55 and a one year high of $68.76. The company’s 50-day simple moving average is $52.89 and its 200 day simple moving average is $54.48. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.24 and a quick ratio of 0.91.

Sonova Company Profile

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.